Term
|
Definition
-malfunctions in neurodevelopment and neurodegenerative changes -changes in anatomy and behavior -NTs-DA,5-HT,glutamate and ACh (we do not know if they are cause or result) |
|
|
Term
neurodegenerative changes most apparent and chaotic at age |
|
Definition
20-40 (apoptosis/necrosis) |
|
|
Term
|
Definition
-caused by excess DA in specific neural tracts (areas high in D2 receptors) -support-most antipsychotics block D2 receptor -the better the drug is at blocking D2 the lower the dose -DA agonists and amphetamines exacerbate it and cause hallucinations -increased DA receptor number in untreated -BUT newer drugs have low affinity for the D2 receptor |
|
|
Term
|
Definition
-conc. where 50% of receptors are inhibited (affinity) -as IC50 increases, dose increases |
|
|
Term
|
Definition
-thinking and mood (mesocortical/mesolimbic) -extrapyramidal function (nigrostriatal) -prolactin release (tuberoinfundibular) -emesis (CTZ trigger zone) |
|
|
Term
D2 (Gi coupled) highly expressed in |
|
Definition
-cortex (arousal/mood) -limbic system (emotion) -striatum (motor control) -ventral hypothalamus/anterior pituitary (dec. prolactin secretion) -blocking DA will block all of these effects and cause adverse effects of antipsychotics |
|
|
Term
|
Definition
-dec. DA in mesolimbic (positive symptoms) -inc. DA in mesocortical (negative and cognitive symptoms) -leave nigrostriatal alone |
|
|
Term
what causes the decrease in DA in mesocortical pathway |
|
Definition
-not sure -DA neurons not producing/releasing enough DA -D2 receptors are blocked by antipsychotic agents -too much 5-HT activity leads to dec. DA release (goal of tx, dec 5-HT in mesocortical pathway) |
|
|
Term
|
Definition
-blood concentration of 5-HT is higher -results in DEC. DA ACTIVITY IN THE MESOCORTICAL PATHWAY -serotonin binds to 5HT2A on glutamatergic neurons which accelerates DA activity in the frontal cortex -leads to ENHANCEMENT OF MESOLIMBIC PATHWAY (POSITIVE SYMPTOMS) |
|
|
Term
serotonin receptor 2 (ABC) |
|
Definition
-CNS, PNS, smooth muscle, platelets -BEHAVIORAL EFFECTS, smooth muscle contraction, platelet aggregation |
|
|
Term
all serotonin receptors are GPCR except |
|
Definition
5-HT3 (sodium potassium channels) |
|
|
Term
|
Definition
-widespread projection originate in raphe nucleus -MANY ROLES: -PSYCHOTIC BEHAVIOR (LSD and MDMA play a role in altering 5-HT) -sleep, depression, OCD, appetite, pain perception, vomiting |
|
|
Term
pure 5-HT antagoists efficacious? |
|
Definition
|
|
Term
why less EPS with drugs that also block 5-HT2A receptors |
|
Definition
-5-HT normally inhibits the nigrostriatal cicuit |
|
|
Term
normal DA 5-HT nigrostriatal pathway |
|
Definition
-DA is released because 5-HT is not binding to 5-HT2A receptor (inhibiting movement) |
|
|
Term
antipsychotic binding to D2 |
|
Definition
-antipsychotic binds only to D2 receptor -5-HT binds to 5-HT2A receptor (dec. DA release) -movement disorders result |
|
|
Term
antipsychotic binding to D2 and 5-HT2A receptors |
|
Definition
-a5-HT cannot bing (inc. DA) -DA competes with antipsychotic for D2 receptor -movement is not inhibited |
|
|
Term
|
Definition
-HYPOfunctional system leads to schizo -LACK of glutamate leads to changes in DA activity associated with schizo -PCP (NMDA antagonist) mimics schizo -changes in expression of NMDA receptors and their associated proteins in schizo |
|
|
Term
|
Definition
-ionotropic (NMDA, AMPA,kainate) -metabotropic (mGluR1-8) |
|
|
Term
lack of glutamatergic activity leads to |
|
Definition
-increase and decrease in DA activity in key areas of the brain |
|
|
Term
|
Definition
-deficits in M1 and M2 receptors and ChAT activity in schizo pts -M receptors play a role in excitability, learning, and memory -many have defect in nACh receptors (alpha4, beta2, and alpha7) -nicotine in attention in smokers -agonists at nicotinic receptors may be effective in treating the cognitive and amerliorate side effects |
|
|
Term
is high incidence of smoking in schizo pts a result of an effort to self medicate |
|
Definition
|
|